GH Research ‘welcomes’ Executive Order to accelerate mental illness treatments

GH Research (GHRS) issued a statement “welcoming” the White House Executive Order, signed on April 18, 2026, to accelerate medical treatments for serious mental illness, including innovative psychedelic medical treatments. The Executive Order directs coordinated federal action to accelerate the development of, and expand patient access to, innovative therapies for serious mental illness. GH Research continues to advance GH001, its proprietary inhaled mebufotenin product candidate, toward initiation of a global pivotal Phase 3 program in treatment-resistant depression in 2026. “We commend the Administration for recognizing the magnitude of the mental health crisis and the urgent need for innovative, evidence-based therapies for patients with serious mental illness. The Executive Order’s emphasis on scientific rigor and cross-agency coordination is well aligned with the approach required to deliver practice-changing treatments, and we remain focused on advancing GH001 toward a global pivotal Phase 3 program,” said Dr. Velichka Valcheva, Chief Executive Officer of GH Research.